These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 3787472)
1. The late effect of subtotal thyroidectomy and radioactive iodine therapy on calcitonin secretion and bone mineral density in women treated for Graves' disease. Lowery WD; Thomas CG; Awbrey BJ; Rosenstein BD; Talmage RV Surgery; 1986 Dec; 100(6):1142-9. PubMed ID: 3787472 [TBL] [Abstract][Full Text] [Related]
2. Axial and appendicular bone mineral density in patients with long-term deficiency or excess of calcitonin. Hurley DL; Tiegs RD; Wahner HW; Heath H N Engl J Med; 1987 Aug; 317(9):537-41. PubMed ID: 3614305 [TBL] [Abstract][Full Text] [Related]
3. Basal plasma levels of calcitonin and bone mineral mass in normal and uremic women. Effect of menopause. Corghi E; Ortolani S; Bianchi ML; Favini P; Vigo P; Polli EE Biomed Pharmacother; 1984; 38(5):263-5. PubMed ID: 6525424 [TBL] [Abstract][Full Text] [Related]
4. Possible effect of calcitonin deficiency on bone mass after subtotal thyroidectomy. Mirzaei S; Krotla G; Knoll P; Koriska K; Köhn H Acta Med Austriaca; 1999; 26(1):29-31. PubMed ID: 10230474 [TBL] [Abstract][Full Text] [Related]
5. Calcitonin secretion in postmenopausal osteoporosis. Tiegs RD; Body JJ; Wahner HW; Barta J; Riggs BL; Heath H N Engl J Med; 1985 Apr; 312(17):1097-100. PubMed ID: 3982469 [TBL] [Abstract][Full Text] [Related]
6. Radioactive iodine treatment in medullary thyroid carcinoma. Faik Erdogan M; Gursoy A; Erdogan G; Kamel N Nucl Med Commun; 2006 Apr; 27(4):359-62. PubMed ID: 16531922 [TBL] [Abstract][Full Text] [Related]
7. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone. Sijanovic S; Karner I Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925 [TBL] [Abstract][Full Text] [Related]
8. Secretion and metabolism of monomeric human calcitonin: effects of age, sex, and thyroid damage. Tiegs RD; Body JJ; Barta JM; Heath H J Bone Miner Res; 1986 Aug; 1(4):339-49. PubMed ID: 3503547 [TBL] [Abstract][Full Text] [Related]
9. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393 [TBL] [Abstract][Full Text] [Related]
10. [Observations on bone mineral metabolism in natural and surgical menopause. Role of synthetic salmon calcitonin and calcium on bone turnover]. Ferrante B; Isa L; Uderzo A Minerva Ginecol; 1993 Mar; 45(3):87-93. PubMed ID: 8332282 [TBL] [Abstract][Full Text] [Related]
11. Androgens and bone mineral content in patients with subtotal thyroidectomy for benign nodular disease. Lakatos P; Tarján G; Mérei J; Földes J; Holló I Acta Med Hung; 1989; 46(4):297-305. PubMed ID: 2636363 [TBL] [Abstract][Full Text] [Related]
12. [Effect of thyroidectomy on bone mineral metabolism. Experimental study in rats]. González Rodríguez MD; Sosa Henríquez M; Limiñana Cañal JM; Bentacor León P An Med Interna; 1990 Oct; 7(10):500-4. PubMed ID: 2104094 [TBL] [Abstract][Full Text] [Related]
13. Radioactive iodine in the treatment of Graves' disease. Al-Kaabi JM; Hussein SS; Bukheit CS; Woodhouse NJ; Elshafie OT; Bererhi H Saudi Med J; 2002 Sep; 23(9):1049-53. PubMed ID: 12370710 [TBL] [Abstract][Full Text] [Related]
14. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine. Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602 [TBL] [Abstract][Full Text] [Related]
15. [Hyperparathyroidism after radioactive iodine therapy for Graves' disease: a case report]. Kawamura J; Tobisu K; Sanada S; Okada Y; Yoshida O; Minami S; Hino M; Shigeno T; Konishi J; Morita R Hinyokika Kiyo; 1983 Nov; 29(11):1513-9. PubMed ID: 6689566 [TBL] [Abstract][Full Text] [Related]
16. [Long-term evolution of immunologic and thyroid function in Graves disease according different therapeutic options]. Campos Pastor MM; Fernández Soto ML; Escobar-Jiménez F; Barredo Acedo F; Ruiz de Almodóvar M Med Clin (Barc); 1994 Apr; 102(12):446-50. PubMed ID: 7516033 [TBL] [Abstract][Full Text] [Related]
17. Radioactive iodine therapy in Graves' hyperthyroidism: a prospective study from a tertiary referral centre in north India. Sankar R; Sekhri T; Sripathy G; Walia RP; Jain SK J Assoc Physicians India; 2005 Jul; 53():603-6. PubMed ID: 16190128 [TBL] [Abstract][Full Text] [Related]
18. Hyperparathyroidism after radioactive iodine therapy for Graves disease. Esselstyn CB; Schumacher OP; Eversman J; Sheeler L; Levy WJ Surgery; 1982 Nov; 92(5):811-3. PubMed ID: 6897129 [TBL] [Abstract][Full Text] [Related]
19. Effect of hyperthyroidism and its treatment on bone mineral content. Toh SH; Claunch BC; Brown PH Arch Intern Med; 1985 May; 145(5):883-6. PubMed ID: 3838875 [TBL] [Abstract][Full Text] [Related]
20. Effect of 131I therapy on serum calcitonin levels in patients with Graves' disease. Földes J; Bános C; Krasznai I; Petrányi G; Steczek K Nuklearmedizin; 1983 Dec; 22(6):320-3. PubMed ID: 6689444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]